Abstract
Miller-Fisher syndrome (MFS) is classified as a variant of Guillain-Barré syndrome (GBS), accounting for 5%-25% of all GBS cases. Since the coronavirus disease-2019 (COVID-19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS-CoV-2 infection test.
Keywords: COVID-19; Guillain-Barré syndrome; Miller-Fisher; SARS-CoV-2; coronavirus; neurofilament light chain; syndrome.
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, Guillain-barrè syndrome, neurofilament light chain, Miller-Fisher, syndrome, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, coronavirus, SARS-COV-2 infection, variant, Infection, severe acute respiratory syndrome Coronavirus, Clinical course, Characteristics, outbreak, Patient, nervous system, neurological manifestations, cerebrospinal fluid, respiratory, Guillain-barrè syndrome, CSF, Evidence, Peripheral nervous system, light chain, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, syndrome, positive, antibody status, Fisher syndrome, neurological manifestation, reported, affecting, 【제목키워드】 nervous system, marker,